{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:02:29Z","timestamp":1767139349575,"version":"build-2238731810"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00228-019-02648-7","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T14:20:43Z","timestamp":1550240443000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2068","authenticated-orcid":false,"given":"Toshinori","family":"Hirai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"issue":"3","key":"2648_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, M JR, Talan DA, Chambers HF (2011) Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18\u2013e55. \n                    https:\/\/doi.org\/10.1093\/cid\/ciq146","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2648_CR2","doi-asserted-by":"publisher","first-page":"e003912","DOI":"10.1136\/bmjopen-2013-003912","volume":"3","author":"AC Kalil","year":"2013","unstructured":"Kalil AC, Klompas M, Haynatzki G, Rupp ME (2013) Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 3(10):e003912. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2013-003912","journal-title":"BMJ Open"},{"issue":"5","key":"2648_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/jac\/dki355","volume":"56","author":"AF Shorr","year":"2005","unstructured":"Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56(5):923\u2013929. \n                    https:\/\/doi.org\/10.1093\/jac\/dki355","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2648_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325\u2013327. \n                    https:\/\/doi.org\/10.1086\/600877","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2648_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"EJ Filippone","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL (2017) The nephrotoxicity of vancomycin. Clin Pharmacol Ther 102(3):459\u2013469. \n                    https:\/\/doi.org\/10.1002\/cpt.726","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2648_CR6","first-page":"379","volume":"69","author":"A Gupta","year":"2011","unstructured":"Gupta A, Biyani M, Khaira A (2011) Vancomycin nephrotoxicity: myths and facts. Neth J Med 69(9):379\u2013383","journal-title":"Neth J Med"},{"issue":"12","key":"2648_CR7","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1128\/AAC.00168-11","volume":"55","author":"JA Bosso","year":"2011","unstructured":"Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD (2011) Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 55(12):5475\u20135479. \n                    https:\/\/doi.org\/10.1128\/aac.00168-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2648_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","volume":"34","author":"EL Cano","year":"2012","unstructured":"Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA, Kett DH (2012) Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther 34(1):149\u2013157. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2011.12.013","journal-title":"Clin Ther"},{"issue":"11","key":"2648_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1345\/aph.1R158","volume":"46","author":"A Horey","year":"2012","unstructured":"Horey A, Mergenhagen KA, Mattappallil A (2012) The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother 46(11):1477\u20131483. \n                    https:\/\/doi.org\/10.1345\/aph.1R158","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2648_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/1060028017720946","volume":"51","author":"YC Choi","year":"2017","unstructured":"Choi YC, Saw S, Soliman D, Bingham AL, Pontiggia L, Hunter K, Chuang L, Siemianowski LA, Ereshefsky B, Hollands JM (2017) Intravenous vancomycin associated with the development of nephrotoxicity in patients with class III obesity. Ann Pharmacother 51(11):937\u2013944. \n                    https:\/\/doi.org\/10.1177\/1060028017720946","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2648_CR11","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52(4):1330\u20131336. \n                    https:\/\/doi.org\/10.1128\/aac.01602-07","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2648_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","volume":"11","author":"GR Matzke","year":"1986","unstructured":"Matzke GR, Zhanel GG, Guay DR (1986) Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 11(4):257\u2013282. \n                    https:\/\/doi.org\/10.2165\/00003088-198611040-00001","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2648_CR13","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982\u2013992. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"2648_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijid.2017.04.018","volume":"60","author":"X Qian","year":"2017","unstructured":"Qian X, Du G, Weng C, Zhou H, Zhou X (2017) Evaluation of the variability and safety of serum trough concentrations of vancomycin in patients admitted to the intensive care unit. Int J Infect Dis 60:17\u201322. \n                    https:\/\/doi.org\/10.1016\/j.ijid.2017.04.018","journal-title":"Int J Infect Dis"},{"issue":"16","key":"2648_CR15","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104(16):1985\u20131991","journal-title":"Circulation"},{"issue":"5","key":"2648_CR16","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1046\/j.1523-1755.2003.00273.x","volume":"64","author":"N Vasavada","year":"2003","unstructured":"Vasavada N, Agarwal R (2003) Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 64(5):1772\u20131779","journal-title":"Kidney Int"},{"issue":"9","key":"2648_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15(9):853\u2013862. \n                    https:\/\/doi.org\/10.1111\/dom.12127","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2648_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1751-7176.2011.00564.x","volume":"14","author":"B Dussol","year":"2012","unstructured":"Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y (2012) A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens 14(1):32\u201337","journal-title":"J Clin Hypertens"},{"issue":"6","key":"2648_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2796.2003.01146.x","volume":"253","author":"G Gambaro","year":"2003","unstructured":"Gambaro G, Perazella MA (2003) Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253(6):643\u2013652","journal-title":"J Intern Med"},{"issue":"2","key":"2648_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.0306-5251.2004.2188.x","volume":"59","author":"KK Loboz","year":"2005","unstructured":"Loboz KK, Shenfield GM (2005) Drug combinations and impaired renal function\u2014the \u2018triple whammy\u2019. Br J Clin Pharmacol 59(2):239\u2013243. \n                    https:\/\/doi.org\/10.1111\/j.0306-5251.2004.2188.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2648_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","volume":"123","author":"L Pritchard","year":"2010","unstructured":"Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB (2010) Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 123(12):1143\u20131149. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2010.07.025","journal-title":"Am J Med"}],"updated-by":[{"DOI":"10.1007\/s00228-019-02671-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02648-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T19:14:54Z","timestamp":1581707694000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02648-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2648"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02648-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"18 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"After online publication, we found a typographical error in Table 2. We consider correcting \u201cVCM trough concentration > 20 g\/mL\u201d to \u201cVCM trough concentration > 20 \u03bcg\/mL\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}